Saw Palmetto Claims Case Set For November Oral Arguments
This article was originally published in The Tan Sheet
FDA argues it never violated First Amendment rights of plaintiffs Julian Whitaker et al. when it denied saw palmetto health claims because they were never considered under the health claim provisions of the Dietary Supplement Health & Education Act
You may also be interested in...
A Washington, D.C. federal court committed a "plain and reversible error" when it upheld FDA's decision to deny a health claim linking saw palmetto extract to the treatment of benign prostatic hyperplasia symptoms, according to an appellate brief filed May 16
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning